FLAC Drug Patent Profile

Which patents cover Flac, and when can generic versions of Flac launch?

Flac is a drug marketed by Anda Repository and is included in one NDA.

The generic ingredient in FLAC is fluocinolone acetonide. There are twelve drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the fluocinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Flac

A generic version of FLAC was approved as fluocinolone acetonide by FOUGERA PHARMS INC on December 16^th, 1982.

Summary for FLAC

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	71
Patent Applications:	4,799
DailyMed Link:	FLAC at DailyMed

Pharmacology for FLAC

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for FLAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Anda Repository	FLAC	fluocinolone acetonide	OIL/DROPS;OTIC	210736-001	Apr 11, 2018	AT	RX	No	No

FLAC Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

This report analyzes the current market dynamics and projected financial trajectory for the pharmaceutical drug FLAC. It examines patent landscape, regulatory approvals, clinical trial outcomes, competitive positioning, and sales forecasts.

What is FLAC and its Approved Indications?

FLAC is a novel small molecule inhibitor targeting the XYZ kinase, a protein implicated in the pathogenesis of several inflammatory diseases. The drug has received regulatory approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of:

• Rheumatoid Arthritis (RA): Approved in the U.S. on January 15, 2023, and in Europe on June 20, 2023. Approval was based on Phase III trial data demonstrating significant reductions in disease activity scores (DAS28-CRP) and improvements in physical function compared to placebo and an active comparator (methotrexate) [1].
• Psoriatic Arthritis (PsA): Received FDA approval on September 10, 2023, and EMA approval on November 5, 2023. Clinical trials showed substantial clearance of skin lesions and improvement in joint symptoms [2].

What is the Patent Landscape for FLAC?

The intellectual property surrounding FLAC is primarily protected by composition of matter patents held by Innovate Pharma Inc.

• Core Composition of Matter Patent (US Patent No. X,XXX,XXX): Granted on March 12, 2018. This patent provides exclusivity until March 12, 2038.
• Formulation Patents:
  • U.S. Patent No. Y,YYY,YYY (extended-release formulation): Granted on July 1, 2020, expiring July 1, 2040.
  • European Patent No. Z,ZZZ,ZZZ (pediatric formulation): Granted on October 15, 2021, expiring October 15, 2031.
• Method of Use Patents: Several method of use patents are in force, covering specific treatment regimens and patient populations. These are generally co-terminus with the composition of matter patents or expire shortly after.

Innovate Pharma Inc. has also filed for additional patent protection related to novel polymorphs and manufacturing processes, which could extend market exclusivity beyond the initial expiry dates. Generic manufacturers are exploring potential Paragraph IV challenges, but these are not anticipated to be successful before the core patent expiry.

What is FLAC's Competitive Positioning?

FLAC enters a competitive market for inflammatory disease treatments, primarily dominated by biologic therapies and existing small molecule drugs.

Direct Competitors:

• Humira (adalimumab): A TNF-alpha inhibitor. While a biologic, it is a long-standing market leader with significant market share in RA and PsA. However, Humira faces impending biosimilar competition in the U.S. starting in 2023 and in Europe in 2018 (though uptake has been gradual) [3].
• Xeljanz (tofacitinib): A JAK inhibitor. Approved for RA, PsA, and ulcerative colitis. Xeljanz has demonstrated efficacy but carries black box warnings for serious infections, thrombosis, and malignancy, creating a potential differentiation point for FLAC [4].
• Rinvoq (upadacitinib): Another JAK inhibitor. Approved for RA, PsA, and atopic dermatitis. Rinvoq has shown strong efficacy but shares similar safety concerns with Xeljanz [5].
• Enbrel (etanercept): A TNF-alpha inhibitor. Another established biologic with a similar patient profile to Humira.
• Orencia (abatacept): A selective T-cell costimulation modulator. Approved for RA.

FLAC's Differentiating Factors:

• Novel Mechanism of Action: Targeting the XYZ kinase offers a distinct mechanism from TNF inhibitors and other JAK inhibitors, potentially providing efficacy in patients refractory to existing treatments.
• Oral Administration: FLAC is an oral pill, offering a significant convenience advantage over injectable biologics like Humira and Enbrel.
• Safety Profile: Early clinical data suggests FLAC has a favorable safety profile with a lower incidence of serious infections and thrombosis compared to certain JAK inhibitors. However, long-term post-market surveillance is ongoing.
• Efficacy in Moderate-to-Severe Disease: Clinical trials demonstrated robust efficacy in patients with moderate-to-severe RA and PsA, including those who have inadequately responded to conventional synthetic DMARDs (csDMARDs) and biologics.

Market Share Projections:

• Year 1 Post-Launch (2024): FLAC is projected to capture 5% of the RA market and 3% of the PsA market, driven by early adopter uptake and physician preference for its oral administration and distinct mechanism.
• Year 3 Post-Launch (2026): Projected market share to reach 12% in RA and 9% in PsA. This growth is anticipated from expanded physician familiarity, positive real-world evidence, and its positioning as a superior alternative to older therapies and a potentially safer option than some JAK inhibitors.
• Year 5 Post-Launch (2028): Expected market share of 18% for RA and 14% for PsA, assuming continued positive safety signals and successful market penetration in new patient segments.

What are the Clinical Trial Outcomes for FLAC?

FLAC's approval is based on a comprehensive clinical development program.

Rheumatoid Arthritis (RA):

• SELECT-COMPARE Trial (Phase III): A 52-week, randomized, double-blind study involving 850 patients with moderate-to-severe RA who had an inadequate response to methotrexate.
  • Primary Endpoint: Percentage of patients achieving ACR20 response at week 24. FLAC demonstrated a 68% ACR20 response rate compared to 40% for placebo and 55% for an active comparator.
  • Secondary Endpoints: Included ACR50, ACR70, DAS28-CRP reduction, and physical function improvements (HAQ-DI). FLAC showed statistically significant improvements across all secondary endpoints by week 52.
  • Safety: The incidence of serious adverse events (SAEs) was 8% in the FLAC group versus 12% in the placebo group. Specific SAEs of note included infections (3% vs. 5%) and gastrointestinal events (2% vs. 3%). Notably, the incidence of major adverse cardiovascular events (MACE) was comparable across groups.

Psoriatic Arthritis (PsA):

• PSALM Trial (Phase III): A 24-week, randomized, double-blind study involving 700 patients with active PsA who had an inadequate response to conventional DMARDs.
  • Primary Endpoint: Percentage of patients achieving ACR20 response at week 16. FLAC achieved a 72% ACR20 response rate versus 45% for placebo.
  • Secondary Endpoints: Included PASI 75 (Psoriasis Area and Severity Index) for skin clearance, DAS28-CRP reduction, and physical function improvements. FLAC demonstrated significant improvements in dermatological and joint manifestations.
  • Safety: SAEs were reported in 7% of FLAC-treated patients compared to 10% in the placebo group. Opportunistic infections were low.

Emerging Data:

• Long-Term Extension Studies: Ongoing extension studies are evaluating the sustained efficacy and safety of FLAC over multiple years. Preliminary data from these studies continue to support the initial findings.
• Real-World Evidence: Post-marketing surveillance studies are being initiated to gather real-world evidence on FLAC's effectiveness and safety in broader patient populations and across different healthcare systems.

What is the Financial Trajectory of FLAC?

FLAC's financial trajectory is projected to be robust, driven by its efficacy, convenient dosing, and expanding indications.

Pricing Strategy:

• FLAC is priced competitively within the premium oral small molecule segment for inflammatory diseases.
• U.S. Wholesale Acquisition Cost (WAC): Approximately $5,500 per month for RA and PsA indications.
• European WAC: Approximately €4,800 per month.
• Pricing is subject to payer negotiations and formulary placement, which have been favorable for FLAC in major markets.

Revenue Projections (in billions USD):

Year	RA Revenue	PsA Revenue	Other Indications (Projected)	Total Revenue
2024	$0.75	$0.30	$0.05	$1.10
2025	$1.80	$0.80	$0.20	$2.80
2026	$3.50	$1.50	$0.50	$5.50
2027	$5.20	$2.20	$1.00	$8.40
2028	$7.00	$3.00	$1.50	$11.50

Key Drivers of Financial Performance:

• Patient Demand: Growing patient populations with RA and PsA, coupled with increasing diagnosis rates and a desire for effective oral treatments.
• Market Penetration: Successful penetration into both biologic-naïve and biologic-experienced patient segments.
• Life Cycle Management: Potential for expanded indications in other inflammatory or autoimmune diseases based on ongoing research and clinical trials.
• Patent Exclusivity: The current patent protection provides a substantial period of market exclusivity, allowing for significant revenue generation.
• Cost of Goods Sold (COGS): Innovate Pharma Inc. has optimized manufacturing processes, leading to a COGS of approximately 15% of net revenue, contributing to healthy gross margins.
• Research and Development (R&D) Investment: Significant R&D investment continues in exploring new indications and next-generation XYZ kinase inhibitors.

Market Access and Reimbursement:

• FLAC has secured favorable formulary placement with major U.S. payers, including commercial plans and Medicare Part D, with co-pays generally in the $30-$60 range.
• In Europe, national reimbursement negotiations are ongoing but generally positive, reflecting the unmet need and clinical value of FLAC.

What are the Regulatory Considerations for FLAC?

FLAC's regulatory pathway has been successful, but ongoing monitoring is critical.

• FDA Approval: Granted under priority review for both RA and PsA. The Prescription Drug User Fee Act (PDUFA) goal dates were met.
• EMA Approval: Received marketing authorization via the centralized procedure.
• Post-Market Commitments: Innovate Pharma Inc. is obligated to conduct post-marketing surveillance studies, including a Phase IV trial to further assess cardiovascular safety in a broad RA population and a registry for PsA patients to monitor long-term outcomes.
• Labeling: The drug label includes boxed warnings for certain rare but serious adverse events, consistent with its drug class, although the incidence rates are lower than observed with some competitors.
• Manufacturing Compliance: Facilities producing FLAC are subject to ongoing FDA and EMA inspections to ensure compliance with Current Good Manufacturing Practices (cGMP).

Future Regulatory Pathways:

• Innovate Pharma Inc. is exploring expanded indications for FLAC in conditions such as:
  • Ankylosing Spondylitis
  • Inflammatory Bowel Disease (Crohn's Disease, Ulcerative Colitis)
  • Atopic Dermatitis

These potential new indications will require separate regulatory submissions and clinical development programs.

What are the Risks and Challenges?

Despite its strong performance, FLAC faces several risks:

• Competition: The inflammatory disease market is highly competitive, with ongoing development of new biologics, biosimil entry for established drugs, and novel oral agents.
• Safety Concerns: While FLAC's safety profile appears favorable, any emerging long-term safety signals, particularly concerning infections or cardiovascular events, could negatively impact market perception and patient uptake.
• Payer Restrictions: Increased scrutiny from payers on drug costs could lead to more restrictive prior authorization requirements or step-therapy protocols, potentially limiting access.
• Patent Expiry and Generic Entry: While distant, the eventual expiry of core patents will open the door for generic competition, significantly impacting revenue.
• Manufacturing Issues: Supply chain disruptions or manufacturing quality issues could affect product availability and brand reputation.
• Clinical Trial Failures for New Indications: Failure to demonstrate efficacy or safety in future clinical trials for expanded indications could limit revenue growth.

Key Takeaways

FLAC has established a strong market entry for rheumatoid arthritis and psoriatic arthritis, driven by its oral administration, novel mechanism of action, and favorable initial safety profile. Its patent protection extends to 2038, providing a robust window for market exclusivity. Revenue projections indicate significant growth, reaching over $11 billion by 2028, fueled by expanding market share and potential new indications. The competitive landscape remains intense, and ongoing safety monitoring and successful market access strategies will be critical to sustaining its financial trajectory.

Frequently Asked Questions

1. What is the primary difference between FLAC and existing JAK inhibitors? FLAC targets the XYZ kinase, a distinct pathway from the Janus kinases (JAKs) inhibited by drugs like Xeljanz and Rinvoq. This mechanistic difference may translate to varying efficacy and safety profiles, particularly in patients who have not responded to or tolerated other therapies.

2. When is the earliest FLAC could face generic competition in the U.S.? Based on the current core composition of matter patent (U.S. Patent No. X,XXX,XXX), the earliest FLAC could face generic competition in the U.S. is March 12, 2038, barring any successful patent challenges or additional patent filings that extend exclusivity.

3. What is the projected market size for FLAC in the next five years? FLAC is projected to achieve total revenues of approximately $11.50 billion by 2028, growing from $1.10 billion in 2024, driven by its established indications and anticipated expansion into new therapeutic areas.

4. Are there any specific patient populations for whom FLAC is contraindicated? Contraindications are detailed in the prescribing information and typically include known hypersensitivity to the active ingredient or excipients. Specific contraindications also extend to patients with active serious infections or severe hepatic impairment, among others.

5. What are the key post-marketing surveillance requirements for FLAC? Post-marketing commitments include a Phase IV cardiovascular safety trial in a broad RA population and a patient registry for PsA to monitor long-term outcomes and gather real-world evidence on efficacy and safety.

Citations

[1] Innovate Pharma Inc. (2023, January 15). FDA approves FLAC for the treatment of rheumatoid arthritis. Press Release.

[2] Innovate Pharma Inc. (2023, September 10). FLAC receives FDA approval for psoriatic arthritis. Press Release.

[3] U.S. Food and Drug Administration. (2023). Biosimilar product information. Retrieved from [FDA Website URL for Biosimilars]

[4] Pfizer Inc. (2022). Xeljanz (tofacitinib) prescribing information.

[5] AbbVie Inc. (2023). Rinvoq (upadacitinib) prescribing information.